Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702

• Status: Completed
• Trial end date: 2009-12-24
• Target enrollment: 0
• Participant gender: All

Summary

GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potential to investigate repeated doses of the study medicine. The study will investigate the following questions, do repeated doses of the study medicine have any important side effects when taken by mouth? How much of the study medicine gets into the bloodstream, and how quickly does the body get rid of it? Does the study medicine affect memory, attention and problem-solving skills? What are the effects when the study medicine and dextromethorphan are taken together.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Dextromethorphan

Criteria

Inclusion Criteria:

• Male or female of non childbearing potential

• Generally healthy

• Body mass index 19 - 29.9 kg/m2 (inclusive), body weight greater than or equal to 50 kg for males and greater than of equal to 45 kg for females

• Normal Laboratory test results

Exclusion Criteria:

• Abuse of drugs or alcohol

• Smoker or history of regular use of tobacco- or nicotine-containing products in the past 6 months

• ECG abnormality (personal or family history)

• Psychiatric disorder

• Asthma or a history of asthma

• Medical illness